Update Reimbursement Scheme Elvanse®
TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg will be extended to adults from 18 years old and above indicated for the treatment of attention deficit hyperactivity disorder (ADHD) with pre-existing symptoms of ADHD in childhood.
Conditions
The Reimbursement Scheme of ELVANSE® is now limited to
- Children 6 years of age and older who are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) when the response to previous treatment with methylphenidate is considered clinically inadequate.
- Adults 18 years of age and older who are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) with pre-existing symptoms of ADHD in childhood.